TABLE 11.2

Clinical trials involving adenovirus vector ^a

Vector

Target

Disease

Number of

trials in phase

1/2 and 2, 3,

& 4

NCT number

Adenovirus

Infectious

diseases

COVID-19

5 (phase 1/2)

NCT05043259;

NCT04436276;

NCT04889209;

NCT04840992;

NCT04398147;

8 (phase 2)

NCT05005156;

NCT04765384;

NCT04341389;

NCT04998240;

NCT04566770;

NCT05000216;

NCT04587219;

NCT05016622

11 (phase 3)

NCT04505722;

NCT04614948;

NCT04540419;

NCT04838795;

NCT04526990;

NCT04510493;

NCT04848467;

NCT04642339;

NCT04540393;

NCT04908722;

NCT04656613

5 (phase 4)

NCT04952727;

NCT04833101;

NCT04892459;

NCT05037266;

NCT05030974;

HIV

6 (phase 1/2)

NCT02919306;

NCT04983030;

NCT02788045;

NCT02099994;

NCT02315703;

NCT02935686

7 (phase 2)

NCT00080106;

NCT03060629;

NCT00350623;

NCT00095576;

NCT00183261;

NCT00976404

272

Bioprocessing of Viral Vaccines